Between January 2010 and November 2012, an electronic search was conducted using MEDLINE (via PubMed), EMBASE, and Cochrane CENTRAL to find studies related to the diagnostic performance of the 2010 ACR/EULAR classification criteria for RA in patients with inflammatory synovitis. Subgroup analyses were performed according to the adopted gold standards. The sensitivity and specificity of the 2010 criteria were extracted or calculated. Summary receiver operating characteristic (sROC) curves were drawn to evaluate the differences between the 2010 and 1987 criteria.
Rheumatoid arthritis (RA) is the most common inflammatory arthritis with a prevalence rate of approximately 1.0% worldwide. [1] With this disease, progressive joint erosion and deformity cause work disability and mortality; thus, early diagnosis and intervention is crucial to ensure a better prognosis. [2] One of the most common criteria, the 1987 American College of Rheumatology (ACR) classification criteria for RA, has been criticized for its lower sensitivity with regard to early arthritis. [3] Therefore, a joint working group from the ACR and the European League Against Rheumatism (EULAR) developed the 2010 classification criteria to identify and facilitate patients at high risk of persistent disease and erosive damage. [4] This criteria contains four categories (joint involvement, serology, acutephase reactants, and duration of symptoms), and a score of ≥6/10 is classified as definite RA since the typical pattern of destructive RA seen on radiographs provides sufficient evidence for this diagnosis, precluding the need for applying additional criteria.
To date, several studies have evaluated the diagnostic performance and discriminative ability of the 2010 criteria. Hence, the aim of this systemic review was to assess the diagnostic values of the 2010 ACR/EULAR criteria for RA and compare them with the 1987 ACR criteria.
PATIENTS AND METHODS
The review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) in November 21, 2012 (No. CRD42012003308), and Checklist 1 for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) is available as supporting information.
Search strategy
We searched the MEDLINE (through PubMed), EMBASE, and Cochrane CENTRAL databases between January 1, 2010 and November 19, 2012 using the following search terms: RA, prevalence, sensitivity, specificity, accuracy. In addition, we also examined the abstracts of the EULAR annual congresses and the ACR annual meetings and also checked the references of the included studies and reviews to search for clues to identify additional relevant studies. There was no language limitation in this search.
Inclusion criteria
The eligibility criteria were the following: (i) A case-control study or cohort study; (ii) Patients with inflammatory synovitis and no other definitive diagnosis other than RA or undifferentiated arthritis (UA); (iii) The use of the 2010 ACR/EULAR classification criteria for RA as the index test along with the initiation of methotrexate (MTX) or diseasemodifying anti-rheumatic drugs (DMARDs) and expert opinion RA (the primary expert's diagnosis of RA) as the reference standard; and (iv) The use of sensitivity and specificity as the primary outcomes so that a 2x2 table (true positive, false positive, true negative, and false negative) could be achieved.
Study selection and data extraction
Two of the authors (Zhang YH and Song WM) of this article independently selected the studies, and disagreements were resolved by discussing or consulting with a third author (Shi GX). The characteristics and outcome data were extracted using the data extraction form for each study. The outcome data, including the sensitivity, specificity, and the 2x2 table, were acquired from the text or calculated using the Review Manager (RevMan) 5.1 software (The Nordic Cochrane Center, the Cochrane Collaboration, Copenhagen, Denmark).
Methodological quality assessment and statistical analysis
The methodological quality of the included studies was assessed using a checklist of 11 items recommended by the Cochrane Collaboration based on Quality Assessment of Diagnostic Accuracy Studies (QUADAS), a tool to determine diagnostic accuracy in systematic reviews. [5] Since clinical heterogeneity was present in the articles used for our review, when assessing the diagnostic values of the 2010 criteria and the 1987 criteria, three subgroups were utilized based on the main gold standards for RA that were adopted in the studies: the MTX group, the DMARD group, and the expert group. The subgroup analyses were conducted according to the gold standards adopted in the included studies. In addition, the heterogeneity of each subgroup was investigated using the Q statistic and I 2 statistic, with p≤0.10 and I 2 ≥50% signifying substantial heterogeneity. If possible, the sensitivity and specificity were pooled, and hierarchical summary receiver operating characteristic (HSROC) curves were launched. A meta-analysis was also conducted under the bivariate binomial mixed model if heterogeneity was present, and summary receiver operating characteristic (SROC) curves were performed to evaluate the differences in diagnostic accuracy between the 2010 ACR/EULAR criteria and 1987 ACR criteria. The Stata 12.0 software program (StataCorp LP, College Station, TX, USA) and RevMan 5.1.5 software for Windows (the Nordic Cochrane Center, the Cochrane Collaboration, Copenhagen, Denmark) were used for all data calculations.
RESULTS

Results of the search
Our electronic search identified 2,438 citations, with 1,461 from PubMed, 915 from EMBASE, and 62 from Cochrane CENTRAL. After the titles and abstracts were screened, 25 full-text articles were retrieved. Of these, only 10 studies [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] were eligible for inclusion. A study flow diagram showing these articles is shown in Figure 1 . [16] Description of the studies These 10 studies included cohorts from the Netherlands, [6] [7] [8] the United States, [13] France, [10] UK, [9] New Zealand, [14] Spain, [15] South Korea, [11] and Japan. [6, 12] The three studies [6] [7] [8] from the Netherlands used different cohort databases: the Rotterdam Early Arthritis Cohort" (REACH), the Stop Arthritis Very Early (SAVE) trial, and the Leiden early arthritis clinic (EAC) cohort). All of the studies enrolled their participants from 2000 onwards when MTX was already widely used as the first line of treatment. Among these studies, three did not aim to calculate the sensitivity and specificity as the outcomes. One attempted to identify the patients according to whether they required DMARDs or MTX, [8] another looked for agreement between the 2010 ACR/EULAR criteria and the 1987 ACR criteria, [9] and one made comparisons between patients with and without RA according to the 2010 ACR/EULAR criteria. [12] Seven studies accepted two or three gold standards while the others only had one gold standard. This was identified as MTX in five studies, [6, [8] [9] [10] 15] DMARDs in seven, [7, [9] [10] [11] [12] 14, 15] and the primary expert's diagnosis of RA in five others. [7, [9] [10] [11] [12] 14, 15] The main characteristics of all of the included studies are provided in Table 1 .
Methodological quality of the included studies
The methodological quality of the included studies was assessed using a checklist recommended by the Cochrane Collaboration based on the QUADAS. 
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Blindness was an important in the evaluation of the methodological quality of the diagnostic accuracy test; however, there was no information related to this item in most of the included studies. Only one article [7] included blindness, and it stated that all patients received a single intramuscular injection of 120 mg of methylprednisolone or a placebo. This achieved the blindness between the interpretation of the index test results and knowledge of the reference standard results. The results of each methodological quality item are presented in Figure 2 , but no funnel plot of publication bias was done because of the small amount of studies included in each group.
Findings
Five studies from Europe that used the 2010 criteria in the MTX group [6, [8] [9] [10] 15] were included in our review. The sensitivity of this group ranged from 0.67 to 0.88, and the specificity was between 0.30 and 0.72. The data was pooled using the bivariate binomial mixed model because of the identified heterogeneity (p<0. Seven studies [7, [9] [10] [11] [12] 14, 15] were included in the DMARD group with a sensitivity between 0.34 and 0.86, and a specificity between 0.40 and 0.78. The expert opinion group (expert group for short) was composed of five studies, [7, 8, 10, 13, 15] be defined within the same model which provides a general framework for the meta-analysis of diagnostic test studies.
Even though most of the included studies did not consider radiographic information when using the 2010 criteria, one study [9] judged a participant with erosion and a score of less than six as being positive under this criteria.
We also evaluated the sensitivity and specificity of the 1987 criteria and found measurements of 0.42-0.82 and 0.40-0.88 in MTX group, 0.38-0.79 and 0.50-0.93 in DMARD group, 0.69-0.94 and 0.49-0.94 in the expert group, respectively. Our data showed that the 2010 criteria had more sensitivity and less specificity in each study. Furthermore, the SROC curves of the 2010 were more accurate in the MTX group but less accurate in the DMARD and expert groups. The SROC curve results for the 1987 and 2010 criteria are given in Figure 5 .
DISCUSSION
Methodological quality
Blindness is an important item that can be utilized to evaluate the methodological quality of diagnostic accuracy tests. Additionally, the interpretation of the results of the index test may be influenced by the knowledge of the results of the reference standard and vice versa. Blindness was the 11 th item in the reporting checklist developed by the Standards for the Reporting of Diagnostic Accuracy (STARD) steering committee. [17] However, it was difficult to assess the blindness item in this review because there was no explicit information for this in most of the included studies.
Diagnostic values of the 2010 criteria
To evaluate the diagnostic value of the 2010 criteria, we did not include the studies which enrolled participants who were not eligible for assessment by the 2010 criteria. The participants with at least one swollen joint and with no diagnosis other than RA or UA represented the spectrum of those who received the test in practice. Under the 2010 criteria, the results of the pooled sensitivity and specificity for the three groups corroborated the findings of another reviewer [18] who presented only the diagnostic values of the 2010 ACR/EULAR criteria for RA but did not compare the 2010 and 1987 criteria.
Difference between the 2010 criteria and the 1987 criteria
Though the data of both the 2010 criteria and the 1987 criteria were not pooled due to the heterogeneity, the data in each study showed that the 2010 criteria had more sensitivity and less specificity than the 1987 criteria. With regard to the SROC, both criteria performed similarly in terms of diagnostic accuracy, but the 2010 criteria did slightly better in the MTX group. Moreover, the lower specificity of the 2010 criteria as it related to the diagnostic criteria could lead to a higher false positive rate and unnecessary treatment, particularly with the potentially toxic DMARDs. In addition, the 2010 criteria had a better discriminative and diagnostic ability which allowed it to identify the risks of symptom persistence and structural damage at an earlier stage. However, the cost-effectiveness of the early initiation of DMARDs is difficult to estimate.
Limitation of the review
There were only 10 studies included, and heterogeneity was significantly identified in this review. After checking the data again, we tried to explore the source of the heterogeneity via a metaregression method but failed because of a lack of valid information. For example, some studies reported the symptom duration using the median data while others used the mean. In actuality, inflammatory arthritis, especially UA, spans a wide spectrum of heterogeneous conditions with a variety of natural courses, and patients from different countries and regions may experience different courses depending on the proportions of benign, self-limiting forms and the development of overt RA. Hence, we believe that more trials are needed to verify the diagnostic values of the 2010 criteria.
The 2010 ACR/EULAR classification criteria did not include erosion in the scoring system in order to focus on the earlier course of the disease. In the later stages of RA, patients with typical erosions were deemed to have prima facie evidence of RA. Only one of the included studies [12] enrolled patients with early arthritis as well as those with a symptom duration of more than three years. Furthermore, another study [9] considered the radiological evidence of erosion by using only RA or UA as a definitive RA under the 2010 ACR/ EULAR criteria. As a classification and diagnosis criteria system, the aim of the 2010 criteria was that it could be applied to all patients.
Conclusion
Although the 2010 ACR/EULAR criteria for RA had a better discriminative and diagnostic ability as well as a higher sensitivity and lower specificity, it cannot be substituted for the 1987 criteria. Further studies are needed that focus on the development and improvement of the diagnostic performance of the 2010 classification criteria for the RA.
